Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Completes Acquisition of Crescendo Bio

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Friday that it completed its acquisition of autoimmune diagnostics firm Crescendo Bioscience.

Myriad paid $245 million in cash for the deal. The total consideration was $270 million minus $25 million for the repayment of a loan made to Crescendo by Myriad in 2011, Myriad said in a document filed with the US Securities and Exchange Commission.

Crescendo, which is keeping its name, will operate as a wholly owned subsidiary of Myriad.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.